Mp61-07 high Risk Disease and Poor Followup: The Role of Renal Mass Biopsy in a Va Cohort

Abstract

response predictive biomarker. However, increased OS has been shown in patients with PBRM-1 LOF mutations and pancreatic metastasis versus without ( HR .34, p[.007). Additionally, PBRM-1 LOF mutations have been associated with less immunogenic, more angiogenic tumor microenvironments, which may portend poorer prognosis. Conflicting or inconclusive evidence exists regarding whether mutated alleles in ERV, mTOR, or VHL are prognostic for OS or PFS. Finally, SETD2 mutations may be associated with metastatic spread to bone.CONCLUSIONS: Overall, we found the strongest consensus for gene mutations in BAP1, CDKN2A, CIMP/FH, and TERT as biomarkers prognostic for OS or PFS, while the prognostic value of PBRM-1, ERV, mTOR, and VHL mutations has yet to be fully elucidated.